Get the Stockscreener App
22.56
2.67%
-0.62
After Hours:
22.06
-0.50
-2.22%
Catalyst Pharmaceuticals Inc stock is traded at $22.56, with a volume of 1.17M.
It is down -2.67% in the last 24 hours and up +9.78% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$23.18
Open:
$23.215
24h Volume:
1.17M
Relative Volume:
0.81
Market Cap:
$2.85B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
19.12
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+4.64%
1M Performance:
+9.78%
6M Performance:
-7.43%
1Y Performance:
+9.51%
1-Day Range:
$22.40
$23.21
1-Week Range:
$21.52
$23.44
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.56 | 2.85B | 460.48M | 142.80M | 221.79M | 1.18 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Relative strength of Catalyst Pharmaceuticals Inc. in sector analysisWeekly Profit Recap & Verified Momentum Stock Watchlist - newser.com
Published on: 2025-11-16 18:06:55 - newser.com
Will Catalyst Pharmaceuticals Inc. stock split again soonJuly 2025 Selloffs & Low Volatility Stock Recommendations - newser.com
Momentum divergence signals in Catalyst Pharmaceuticals Inc. chartJuly 2025 Intraday Action & Expert Verified Movement Alerts - newser.com
Why Catalyst Pharmaceuticals Inc. stock is considered a top pickEarnings Beat & Technical Pattern Alert System - newser.com
How Catalyst Pharmaceuticals Inc. (CN2) stock stacks up against competitorsJuly 2025 Patterns & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-11-15 17:29:47 - newser.com
Published on: 2025-11-15 11:24:50 - newser.com
Is Catalyst Pharmaceuticals Still a Bargain After Pipeline Expansion and 8% Weekly Gain? - Yahoo Finance
Using portfolio simulators with Catalyst Pharmaceuticals Inc. included2025 Trading Volume Trends & Daily Growth Stock Investment Tips - newser.com
What analyst consensus says on Catalyst Pharmaceuticals Inc. stockTrade Volume Summary & High Win Rate Trade Alerts - newser.com
STATE STREET CORP's Strategic Acquisition of Catalyst Pharmaceuticals Inc Shares - GuruFocus
Insider Sell: Brian Elsbernd Sells 40,000 Shares of Catalyst Pha - GuruFocus
Published on: 2025-11-14 16:42:00 - newser.com
Why Catalyst Pharmaceuticals Inc. stock is favored by pension fundsJuly 2025 Rallies & Target Return Focused Stock Picks - newser.com
Why hedge funds are buying Catalyst Pharmaceuticals Inc. stockLayoff News & Community Verified Trade Signals - Fundação Cultural do Pará
Price momentum metrics for Catalyst Pharmaceuticals Inc. explainedQuarterly Portfolio Report & AI Powered Market Entry Strategies - newser.com
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - sharewise.com
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - sharewise.com
Applying Elliott Wave Theory to Catalyst Pharmaceuticals Inc.2025 Analyst Calls & AI Driven Price Predictions - newser.com
Is Catalyst Pharmaceuticals Inc. (CN2) stock a buy on weaknessChart Signals & Free Accurate Trade Setup Notifications - newser.com
Wall Street Analysts Believe Catalyst (CPRX) Could Rally 51.45%: Here's is How to Trade - Finviz
Why global investors buy Catalyst Pharmaceuticals Inc. (CN2) stockGDP Growth & Verified Trade Idea Suggestions - newser.com
Will Catalyst Pharmaceuticals Inc. (CN2) stock keep high P E multiplesPortfolio Update Summary & Verified High Yield Trade Plans - newser.com
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):